202 related articles for article (PubMed ID: 25907546)
21. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; Bewersdorf JP; Xie Z; Porta MGD; Komrokji R; Xu ML; Abdel-Wahab O; Taylor J; Steensma DP; Starczynowski DT; Sekeres MA; Sanz G; Sallman DA; Roboz GJ; Platzbecker U; Patnaik MM; Padron E; Odenike O; Nimer SD; Nazha A; Majeti R; Loghavi S; Little RF; List AF; Kim TK; Hourigan CS; Hasserjian RP; Halene S; Griffiths EA; Gore SD; Greenberg P; Figueroa ME; Fenaux P; Efficace F; DeZern AE; Daver NG; Churpek JE; Carraway HE; Buckstein R; Brunner AM; Boultwood J; Borate U; Bejar R; Bennett JM; Wei AH; Santini V; Savona MR; Zeidan AM
Blood Rev; 2023 Nov; 62():101128. PubMed ID: 37704469
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world].
Gao QY; Li B; Qu SQ; Pan LJ; Jiao M; Zhao JY; Xu ZF; Xiao ZJ; Qin TJ
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):156-162. PubMed ID: 38604792
[No Abstract] [Full Text] [Related]
23. Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.
Stojkov I; Conrads-Frank A; Rochau U; Arvandi M; Koinig KA; Schomaker M; Mittelman M; Fenaux P; Bowen D; Sanz GF; Malcovati L; Langemeijer S; Germing U; Madry K; Guerci-Bresler A; Culligan DJ; Kotsianidis I; Sanhes L; Mills J; Puntscher S; Schmid D; van Marrewijk C; Smith A; Efficace F; de Witte T; Stauder R; Siebert U
Blood Adv; 2023 Jun; 7(12):2772-2783. PubMed ID: 36607832
[TBL] [Abstract][Full Text] [Related]
24. Autoimmune manifestations associated with myelodysplastic syndrome predict a poor prognosis.
Arinobu Y; Kashiwado Y; Miyawaki K; Ayano M; Kimoto Y; Mitoma H; Akahoshi M; Miyamoto T; Horiuchi T; Akashi K; Niiro H
Medicine (Baltimore); 2021 Apr; 100(13):e25406. PubMed ID: 33787649
[TBL] [Abstract][Full Text] [Related]
25. MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients.
Larfors G; Moreno Berggren D; Garelius H; Nilsson L; Rasmussen B; Hellström-Lindberg E; Ejerblad E
Leuk Res; 2023 Nov; 134():107386. PubMed ID: 37690322
[TBL] [Abstract][Full Text] [Related]
26. P53 IHC Result as a Prognostic Tool in MDS.
Rezvani A; Monabati A; Kargar Z; Safaei A; Mahmoodzadeh M; Moosapour H; Hosseini M; Taheri A; Kheiri S; Taheri E
Iran J Pathol; 2023; 18(3):327-334. PubMed ID: 37942201
[TBL] [Abstract][Full Text] [Related]
27. Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes.
Yao CY; Lin CC; Wang YH; Kao CJ; Tsai CH; Hou HA; Tien HF; Hsu CL; Chou WC
Blood Adv; 2024 May; 8(10):2442-2454. PubMed ID: 38527292
[TBL] [Abstract][Full Text] [Related]
28. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
DeZern AE; Greenberg PL
Blood; 2023 Dec; 142(26):2258-2267. PubMed ID: 37562001
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA; Gregorio C; Robin M; Gagelmann N; Gurnari C; Ball S; Caballero Berrocal JC; Lanino L; D'Amico S; Spreafico M; Maggioni G; Travaglino E; Sauta E; Meggendorfer M; Zhao LP; Campagna A; ; Savevski V; Santoro A; Al Ali N; Sallman D; Sole F; Garcia-Manero G; Germing U; Kroger N; Kordasti S; Santini V; Sanz G; Kern W; Platzbecker U; Diez-Campelo M; Maciejewski JP; Ades L; Fenaux P; Haferlach T; Zeidan AM; Castellani G; Komrokji R; Ieva F; Della Porta MG
J Clin Oncol; 2024 May; ():JCO2302175. PubMed ID: 38723212
[TBL] [Abstract][Full Text] [Related]
30. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).
Abel GA; Efficace F; Buckstein RJ; Tinsley S; Jurcic JG; Martins Y; Steensma DP; Watts CD; Raza A; Lee SJ; List AF; Klaassen RJ
Haematologica; 2016 Jun; 101(6):781-8. PubMed ID: 26944474
[TBL] [Abstract][Full Text] [Related]
31. [Myelodysplastic syndrome : prognostic factors].
Gyan E; Thépot S
Bull Cancer; 2023 Nov; 110(11):1141-1146. PubMed ID: 37537115
[TBL] [Abstract][Full Text] [Related]
32. Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine-A Retrospective Analysis.
Wiśniewski K; Pruszczyk-Matusiak K; Puła B; Lech-Marańda E; Góra-Tybor J
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611011
[TBL] [Abstract][Full Text] [Related]
33. Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS).
Uno H; Cronin AM; Wadleigh M; Schrag D; Abel GA
Leuk Res; 2014 Dec; 38(12):1420-4. PubMed ID: 25443886
[TBL] [Abstract][Full Text] [Related]
34. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes.
Ma X; Wang R; Galili N; Mayne ST; Wang SA; Yu H; Raza A
Cancer Causes Control; 2011 Apr; 22(4):623-9. PubMed ID: 21287258
[TBL] [Abstract][Full Text] [Related]
35. A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes.
Boccia R; Xiao H; von Wilamowitz-Moellendorff C; Raorane R; Deshpande S; Klijn SL; Yucel A
J Clin Med; 2024 May; 13(9):. PubMed ID: 38731231
[TBL] [Abstract][Full Text] [Related]
36. Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia.
Qiao W; Young E; Feng C; Liu S; Jin J; Noor L; Rojas Hernandez CM; Borthakur G; Gorlova O; Afshar-Kharghan V
Exp Hematol Oncol; 2022 Sep; 11(1):58. PubMed ID: 36114519
[TBL] [Abstract][Full Text] [Related]
37. Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?
Scheid C; Eikema DJ; Van Gelder M; Salmenniemi U; Maertens J; Passweg JR; Blaise D; Byrne JL; Kroeger N; Sockel K; Chevallier P; Bourhis JH; Cornelissen JJ; Sengeloev H; Finke J; Snowden JA; Gedde-Dahl T; Cornillon J; Schanz U; Patel A; Koster L; de Wreede LC; Hayden PJ; Raj K; Drozd-Sokolowska J; Gurnari C; Onida F; McLornan DP; Robin M; Yakoub-Agha I
Blood; 2024 May; ():. PubMed ID: 38728380
[TBL] [Abstract][Full Text] [Related]
38. Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.
Inoue Y; Okamoto H; Miyashita A; Kawaji-Kanayama Y; Chinen S; Fujino T; Tsukamoto T; Shimura Y; Mizutani S; Kaneko H; Kuwahara-Ota S; Fuchida SI; Nishiyama D; Hirakawa K; Uchiyama H; Uoshima N; Kawata E; Kuroda J
Oncol Lett; 2024 Feb; 27(2):62. PubMed ID: 38192677
[TBL] [Abstract][Full Text] [Related]
39. Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival.
Steinmetz HT; Toczek-Thiel J; Lipke J; Liersch R; Sauer A; Tesch H; Heßling J; Totzke U; Schmitz S
Leuk Lymphoma; 2023; 64(8):1476-1479. PubMed ID: 37254711
[No Abstract] [Full Text] [Related]
40. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms.
Merz AMA; Platzbecker U
Exp Hematol; 2024 Feb; 130():104130. PubMed ID: 38036096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
